Abstract
Introduction Diagnosis of degenerative cervical myelopathy (DCM) is primarily based on clinical evaluation and evidence of cervical spinal cord compression on conventional MRI. However, delays in diagnosis are common in DCM and there is a need for additional objective assessments of spinal cord structure and function. Serum proteins are increasingly being used as biomarkers for neurological disorders and are promising targets for biomarker discovery in DCM. The objective of this study was to profile serum protein biomarkers in DCM and determine if serum proteins can aid diagnosis and prognosis in DCM.
Methods Patients with a clinical diagnosis of DCM and scheduled to undergo decompressive surgery were prospectively enrolled from July 2022 to August 2023. Serum was obtained prior to surgery and at 3 months after surgery. Serum neuronal and inflammatory proteins were quantified using ultrasensitive single-molecular array technology. Serum biomarker concentrations were compared between DCM patients and age- and sex-matched healthy controls. Robust logistic regression was used to determine the panel of serum biomarkers that best differentiated DCM and controls. Serum biomarkers were also related to pre- and post-surgical functional measurements using linear regression.
Results Twenty DCM patients (median age 70 years, 10 females) and 10 healthy controls (median age 65 years, 5 females) were enrolled. Pre-surgical NfL (30.2 vs 11.2 pg/ml, p=0.01) and IL-6 (2.9 vs 1.2, p=0.003) was significantly higher in DCM patients compared to controls. Pre-surgical NfL, IL-6 and BDNF best differentiated DCM and controls (p<0.001). At 3 months after surgery, significant increase in serum BDNF (p=0.001), AB-42 (p=0.042) and TNFa (p=0.007) were noted. Pre-surgical serum NfL was significantly associated improvement in pinch strength after surgery (p<0.05). Inflammatory biomarkers were linked to improvement in the neck pain-related disability and upper limb function assessed by the QuickDASH.
Conclusion A pre-surgical serum panel of NfL, IL-6 and BDNF may aid in the diagnosis of DCM. Serum NfL is elevated in DCM and is associated with improvement in post-surgical objective measures of upper limb function. Pre-surgical serum neuronal and inflammatory biomarkers predict early post-surgical functional outcomes in DCM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH/NINDS
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical College of Wisconsin IRB gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
